Careers
Arthrosi Therapeutics offers career opportunities and describes its work environment as flexible, diverse, and dynamic.

Arthrosi Therapeutics is a private late-stage biotechnology company developing pozdeutinurad, an investigational URAT1 inhibitor for progressive and tophaceous gout.
arthrosi.comCrawled Oct 15, 2026
Arthrosi Therapeutics offers career opportunities and describes its work environment as flexible, diverse, and dynamic.
The company aims to develop medicines and targeted therapies with the potential to improve quality of life for patients.
The team takes risks to find solutions to challenges in rare diseases and aims to improve patients’ lives.
Arthrosi was founded by a team of gout experts and aims to understand and change the lives of patients and those who help them.
Arthrosi Therapeutics offers clinical strategy partnerships in the biotech industry.
Arthrosi is a clinical-stage biotech company focused on developing a therapy for gout and chronic kidney diseases.
Arthrosi Therapeutics’ submission policy describes how the company collects, uses, maintains, and discloses information from visitors to arthrosi.com.
Swedish Orphan Biovitrum (Sobi) has acquired Arthrosi Therapeutics to expand its pipeline of treatments targeting gout. The deal integrates Arthrosi’s research into Sobi’s existing portfolio, aiming to advance therapeutic options for inflammatory arthritis. Both companies specialize in rare and severe diseases, with Sobi focusing on biopharmaceuticals.
Sobi is acquiring Arthrosi Therapeutics to add a Phase 3 asset targeting gout. The deal expands Sobi’s pipeline with a novel treatment candidate, positioning the company to advance its mid- to long-term growth and profitability in rare and inflammatory diseases. The acquisition underscores Sobi’s focus on developing differentiated therapies for unmet medical needs.
Sobi acquires Arthrosi Therapeutics for $950 million to integrate **pozdeutinurad**, a Phase III gout treatment candidate, into its pipeline. The deal aims to bolster Sobi’s focus on rare and inflammatory diseases. Arthrosi’s drug is currently under late-stage clinical evaluation for managing gout symptoms.
Arthrosi raises **$153 million in Series E funding** to finalize development of **pozdeutinurad**, a gout and tophaceous gout treatment. The company completes enrollment in **REDUCE 1 and REDUCE 2 Phase 3 trials**, with pivotal data anticipated in **Q2 2026**. The funding supports late-stage validation of the drug’s efficacy and regulatory submission.
Arthrosi Therapeutics completes enrollment for its second pivotal Phase 3 trial of **pozdeutinurad (AR882)** in gout patients, including those with severe tophaceous gout. The trial finishes ahead of schedule, following the full enrollment of the first Phase 3 study. Both trials’ data are now expected in **Q2 2026** to support regulatory submissions.